Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | PDE5A | O76074 | 17/20 | 0.68 |
| ▸ | PDE2A | O00408 | 1/20 | 0.67 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.67 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.67 |
| ▸ | PDE6D | O43924 | 1/20 | 0.67 |
| ▸ | PDE8A | O60658 | 1/20 | 0.67 |
| ▸ | PDE9A | O76083 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | PDE6A | P16499 | 1/20 | 0.67 |
| ▸ | PDE6G | P18545 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | PDE6B | P35913 | 1/20 | 0.67 |
| ▸ | PDE6C | P51160 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8231278 | 1.00 | KMT2A (0.88) | KMT2AKDM4EPDE5APDE2AABCC4 | |
| SCHEMBL1253 | 0.91 | KMT2A (0.73) | KMT2AKDM4EPDE5APDE2AABCC4 | |
| SCHEMBL31202676 | 0.91 | KMT2A (0.73) | KMT2AKDM4EPDE5APDE2AABCC4 | |
| SCHEMBL28417921 | 0.87 | PDE5A (0.89) | PDE5APDE2AABCC4ABCC5PDE6D | |
| SCHEMBL7965689 | 0.86 | PDE5A (0.67) | KMT2AKDM4EPDE5APDE2AABCC4 | |
| SCHEMBL7000981 | 0.86 | KDM4E (0.71) | KMT2AKDM4EPDE5APDE2AABCC5 | |
| SCHEMBL997 | 0.86 | PDE5A (0.89) | PDE5APDE2AABCC4ABCC5PDE6D | |
| SCHEMBL13990470 | 0.86 | POLB (0.89) | KMT2AKDM4EPDE5APDE2APDE9A | |
| SCHEMBL26766365 | 0.86 | KMT2A (0.66) | KMT2AKDM4EPDE5APDE2AABCC4 | |
| SCHEMBL6628860 | 0.85 | KMT2A (0.85) | KMT2AKDM4EPDE5APDE2AABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576081-B2 | Methods and compositions for improving exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in single ventricular heart disease, using udenafil compositions | MEZZION PHARMA CO., LTD. (KR) | 2026-03-17 | — | — | US | disclosed |
| US-20250186448-A1 | FORMULATIONS OF UDENAFIL | MEZZION PHARMA CO LTD (KR) | 2025-06-12 | — | — | US | disclosed |
| CN-119072312-A | Methods and compositions for improving athletic performance | 美智恩制药公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-4452273-A1 | METHODS AND COMPOSITIONS FOR IMPROVING EXERCISE PERFORMANCE | Mezzion Pharma Co., Ltd. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240285630-A1 | Methods and compositions for improving exercise performance | MEZZION PHARMA CO., LTD. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240197736-A1 | METHODS AND COMPOSITIONS FOR IMPROVING EXERCISE PERFORMANCE, SINGLE VENTRICULAR PERFORMANCE, CARDIAC OUTPUT AND MYOCARDIAL PERFORMANCE INDEX (MPI) IN SINGLE VENTRICULAR HEART DISEASE, USING UDENAFIL COMPOSITIONS | MEZZION PHARMA CO., LTD. (KR) | 2024-06-20 | — | — | US | disclosed |
| US-20230218622-A1 | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC LIVER CONDITIONS, USING UDENAFIL COMPOSITIONS | MEZZION PHARMA CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| WO-2023121689-A1 | METHODS AND COMPOSITIONS FOR IMPROVING EXERCISE PERFORMANCE | MEZZION PHARMA CO., LTD. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023018972-A1 | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC LIVER CONDITIONS, USING UDENAFIL COMPOSITIONS | MEZZION PHARMA CO., LTD. (KR) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218622-A1 | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC LIVER CONDITIONS, USING UDENAFIL COMPOSITIONS | FGF1, SLC10A1, HDGF | KMT2A 2838/4885KDM4E 887/4885PDE5A 81/4885 |
| US-20250186448-A1 | FORMULATIONS OF UDENAFIL | SLC10A1, FGF1, SLC10A2 | KMT2A 2721/4885KDM4E 793/4885PDE5A 37/4885 |
| US-20240197736-A1 | METHODS AND COMPOSITIONS FOR IMPROVING EXERCISE PERFORMANCE, SINGLE VENTRICULAR PERFORMANCE, CARDIAC OUTPUT AND MYOCARDIAL PERFORMANCE INDEX (MPI) IN SINGLE VENTRICULAR HEART DISEASE, USING UDENAFIL COMPOSITIONS | TNNT2, NPPA, TNNI3 | KMT2A 2808/4885KDM4E 1137/4885PDE5A 5/4885 |
| US-20240285630-A1 | Methods and compositions for improving exercise performance | MAX, FABP3, TNNT2 | KMT2A 1716/4885KDM4E 2150/4885PDE5A 907/4885 |
| US-12576081-B2 | Methods and compositions for improving exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in single ventricular heart disease, using udenafil compositions | TNNT2, TNNI3, NPPA | KMT2A 2917/4885KDM4E 1100/4885PDE5A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.